©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2017; 23(42): 7495-7504
Published online Nov 14, 2017. doi: 10.3748/wjg.v23.i42.7495
Published online Nov 14, 2017. doi: 10.3748/wjg.v23.i42.7495
Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
Ahad Eshraghian, Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz 71937-11351, Iran
Author contributions: Eshraghian A was contributed to study design, data retraction, review of articles, drafting of the manuscript, revising it and approval.
Conflict-of-interest statement: No conflict of interest to declare.
Correspondence to: Ahad Eshraghian, MD, Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz 71937-11351, Iran. eshraghiana@yahoo.com
Telephone: +98-71-36281442 Fax: +98-71-36281442
Received: June 7, 2017
Peer-review started: June 8, 2017
First decision: July 13, 2017
Revised: September 14, 2017
Accepted: September 19, 2017
Article in press: September 19, 2017
Published online: November 14, 2017
Processing time: 158 Days and 15.9 Hours
Peer-review started: June 8, 2017
First decision: July 13, 2017
Revised: September 14, 2017
Accepted: September 19, 2017
Article in press: September 19, 2017
Published online: November 14, 2017
Processing time: 158 Days and 15.9 Hours
Core Tip
Core tip: Non-alcoholic fatty liver disease (NAFLD) is an increasing liver disease worldwide. However, most of patients are treated with life style modification including weight loss and dietary regimen. Pharmacologic therapy may be indicated in a group of patients with non-alcoholic steatohepatitis. Here in, the current and emerging medications for treatment of NAFLD was reviewed briefly with regard of their beneficial effects on histological outcomes.